TP53 or Not TP53: That Is the Question

被引：0

作者：

Green, Steven D. ^{[1
]}

Zeidner, Joshua F. ^{[2
,3
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[3] Univ N Carolina, Dept Med, Div Hematol, 170 Manning Dr,Houpt Bldg,CB7305, Chapel Hill, NC 27599 USA

来源：

CLINICAL CANCER RESEARCH | 2022年 / 28卷 / 24期

关键词：

ACUTE MYELOID-LEUKEMIA; CLASSIFICATION; VALIDATION;

D O I：

10.1158/1078-0432.CCR-22-2664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics does not appear to benefit from the addition of venetoclax to azacitidine. This has clinical implications as these patients should be preferentially treated with alternative regimens.

引用

页码：5235 / 5237

页数：3

共 50 条

[1] TP53 in Myelodysplastic Syndromes
Jiang, Yan
Gao, Su-Jun
Soubise, Benoit
Douet-Guilbert, Nathalie
Liu, Zi-Ling
Troadec, Marie-Berengere
CANCERS, 2021, 13 (21)
[2] Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency
Zhao, Davidson
Eladl, Entsar
Zarif, Mojgan
Capo-Chichi, Jose-Mario
Schuh, Andre
Atenafu, Eshetu
Minden, Mark
Chang, Hong
CANCER MEDICINE, 2023, 12 (06): : 6511 - 6522
[3] Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
Tam, Benjamin
Sinha, Siddharth
Qin, Zixin
Wang, San Ming
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
[4] TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
Wang, Haiwei
Wang, Xinrui
Xu, Liangpu
Zhang, Ji
BMC GENOMIC DATA, 2022, 23 (01):
[5] TP53 polymorphism in plasma cell myeloma
Zmorzynski, Szymon Andrzej
Korszen-Pilecka, Iwona
Wojcierowska-Litwin, Magdalena
Kwiatkowska-Drabik, Barbara
Luterek, Malgorzata
Chocholska, Sylwia
Koczkodaj, Dorota
Popek, Sylwia
Michalak-Wojnowska, Malgorzata
Swiderska-Kolacz, Grazyna
Januszewska, Joanna
Surowiec, Iwona
Tomczak, Waldemar
Hus, Marek
Dmoszynska, Anna
Pasiarski, Marcin
Poniewierska-Jasak, Katarzyna
Cieplinska, Katarzyna
Jankowska-Lecka, Olga
Filip, Agata Anna
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2017, 55 (04) : 203 - 211
[6] TP53 in adult acute lymphoblastic leukemia
Salmoiraghi, Silvia
Rambaldi, Alessandro
Spinelli, Orietta
LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 778 - 789
[7] Targeting TP53 Mutations in Myelodysplastic Syndromes
Hunter, Anthony M.
Sallman, David A.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (02) : 421 - +
[8] Patterns of mutations in TP53 mutated AML
Welch, John S.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (04) : 379 - 383
[9] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
Stengel, A.
Kern, W.
Haferlach, T.
Meggendorfer, M.
Fasan, A.
Haferlach, C.
LEUKEMIA, 2017, 31 (03) : 705 - 711
[10] NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells
Zhang, Yu
Yu, Hao
He, Mengyao
Liu, Wenchao
Xiao, Shengyou
Wang, Xiangting
Huang, Ping
Huang, Qiang
NEOPLASMA, 2024, 71 (03) : 255 - 265

← 1 2 3 4 5 →